- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Ursodeoxycholic Acid Therapy for Dissolving Gallstones
-
- OKUMURA Makoto
- First Department of Internal Medicine, Fukuoka University School of Medicine
-
- TANIKAWA Kyuichi
- Second Department of Medicine, Kurume University School of Medicine
-
- CHUMAN Yasuo
- Internal Medicine, Second Department, Kagoshima University
-
- KOJI Toshihiko
- First Department of Internal Medicine, Nagasaki University School of Medicine
-
- NAKAGAWA Shoso
- Third Department of Internal Medicine, Kumamoto University Medical School
-
- NAKAMURA Yuichi
- Fukuoka City, Medical Association Hospital
-
- IINO Haruhiko
- Wakamatsu Municipal Hospital of Kitakyushu City
-
- YAMASAKI Seiichiro
- Department of Internal Medicine and Clinical Laboratory, Kurume University School of Medicine
-
- HISATSUGU Takeharu
- First Department of Surgery, Faculty of Medicine, Kyushu University
Bibliographic Information
- Other Title
-
- ウルソデオキシコール酸長期投与による胆石症の治療
Search this article
Description
Ursodeoxycholic acid (UDCA), 7-β hydroxy epimer of chenodeoxycholic acid.(CDCA), has been used as a choleretica for 20 years in Japan. Recent report showing increased formationof UDCA in patients treated with CDCA may suggest that UDCA has similar effectto CDCA on bile cholesterol unsaturation. This paper describes the clinical value of UDCAfor the treatment of gallstones.<BR>Seventy-eight patients (22 men and 56 women) who have radiolucent or radiopaquegallstones in functioning gallbladder were studied. UDCA, supplied in tablets (Ursosan®), was given orally 450 mg/day for an average of 6.7 months.<BR>The diappearance or reduction of gallstone size or number or both (dissolving effect) was recognized in 29 of 78 patients (37%). In case of rediolucent stones, dissolving effectwas evaluated in 19 of 43 patients (44%). Diarrhea, troublesame side-effect reported in CDCAtreatment, was only occasionally observed in 4 patients. No other abnormalities was encounteredduring UDCA treatment.<BR>Although the descrimination between CDCA and UDCA in the gallstone dissolutionefficacy remains to be determined, our own results may indicate that UDCA offer a usefultreatment for cholesterol gallstones in functioning gallbladder.
Journal
-
- Nippon Shokakibyo Gakkai Zasshi
-
Nippon Shokakibyo Gakkai Zasshi 74 (8), 1030-1041, 1977
The Japanese Society of Gastroenterology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282681376465536
-
- NII Article ID
- 130001530163
-
- ISSN
- 13497693
- 04466586
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed